Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322539 · ClinicalTrials.gov registry record · Phase 3
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Hutchison Medipharma Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 691
- Enrollment target
NCT04322539 is a Phase 3 study that has completed, run by Hutchison Medipharma Limited. The registered enrollment target is 691 participants.
The verdict
NCT04322539, a Phase 3 study, has completed, sponsored by Hutchison Medipharma Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 691 participants
- Enrollment target
Study Summary
This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.
Interventions
- DRUG Placebo
- DRUG Fruquintinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 691 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04322539
The ClinicalTrials.gov registry entry for NCT04322539 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 691 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchison Medipharma Limited, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04322539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04322539 about?
NCT04322539 is a clinical study titled "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer". This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in participants with refractory metastatic colorectal cancer (mCRC). 691 participants were ran...
What is the current status of trial NCT04322539?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 691 participants. The study started on 2020-08-12. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT04322539?
The interventions under investigation include: Placebo (DRUG), Fruquintinib (DRUG).
Who is sponsoring clinical trial NCT04322539?
This trial is sponsored by Hutchison Medipharma Limited, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.